Liver Stem Cell Expansion Using EGFL6 Culture Medium
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing liver cells, especially liver stem cells, face challenges in reproducibly generating large numbers of cells that can differentiate into hepatocytes, cholangiocytes, and liver sinusoidal endothelial cells (LSEC) for liver tissue reconstitution and experimental animal models, with limitations in scalability and genetic stability.
Innovation Solution
A process involving the use of human epidermal growth factor-like protein 6 (EGFL6) in cell culture medium to cultivate primary liver cells, which results in the production of liver stem cells that can be expanded in number and differentiated into hepatocytes, cholangiocytes, and LSEC, using static culture conditions and protease treatment of liver biopsies to enhance stem cell production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods are used to produce liver cells, then some liver cells can be obtained, but the number of cells is insufficient and they cannot reliably differentiate into all required liver cell types
Solution Approach 1:
The patent changes the biochemical parameters of the culture medium by adding EGFL6 protein and optimizing concentrations of hepatocyte growth factor (HGF) and fibroblast growth factor 4 (FGF4). This parameter change enables the culture medium to support both high cell proliferation and reliable differentiation into hepatocytes, cholangiocytes, and LSEC, resolving the contradiction between productivity and reliability.
Solution Approach 2:
The patent introduces EGFL6 as an intermediary substance in the culture medium that mediates between cell proliferation and differentiation signals. EGFL6 works synergistically with HGF and FGF4 to create an optimal environment that simultaneously supports high cell numbers and maintains differentiation capability, thus resolving the contradiction.
2Productivity
If liver stem cells are cultivated to increase cell number, then productivity improves, but genetic stability and stem cell capability may be lost
Solution Approach 1:
The patent optimizes culture medium parameters including EGFL6 concentration, HGF concentration, and FGF4 concentration to create conditions that support both cell proliferation and genetic stability. The specific parameter combination ensures that cells can be expanded while maintaining their stem cell characteristics and genetic integrity.
Solution Approach 2:
The patent implements a feedback mechanism by monitoring cell morphology, marker expression, and differentiation capability during cultivation. This feedback allows adjustment of culture conditions to maintain genetic stability and stem cell capability while achieving the desired cell number increase.
3Quantity of substance
If large numbers of liver stem cells are produced for tissue reconstitution, then the quantity requirement is met, but the complexity of maintaining differentiation potential increases
Solution Approach 1:
The patent creates a universal culture medium formulation that simultaneously performs multiple functions: supporting cell proliferation, maintaining stem cell capability, and enabling differentiation into hepatocytes, cholangiocytes, and LSEC. This multi-functional medium reduces the need for complex, separate culture systems for different cell types.
Solution Approach 2:
The patent optimizes specific parameter combinations in the culture medium (EGFL6, HGF, FGF4 concentrations) to achieve a simplified culture system that can produce large numbers of liver stem cells while maintaining their differentiation potential, thus reducing overall system complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process efficiently produces liver stem cells that are genetically identical and stable, capable of differentiating into functional liver cell types, suitable for treating liver defects and generating experimental animals with human liver tissue, while avoiding immune rejection and tumorigenic transformation.
Implementation Method 1
The liver cells originating from a sample of liver tissue are incubated in cell culture medium under cell culture conditions, wherein the culture medium contains EGFL6
Implementation Method 2
protease treatment of liver biopsies to enhance stem cell production
Implementation Method 3
liver stem cells that can be expanded in number and differentiated into hepatocytes, cholangiocytes, and LSEC
Data Source
AI summary
The present invention relates to a process for producing liver cells, especially liver stem cells, which after injection into a mammal or in vitro form liver cells that are differentiated, especially differentiated into hepatocytes, into cholangiocytes, and preferably also into liver sinusoidal endothelial cells (LSEC) that can e.g. form blood sinusoidal capillaries. The invention is based on in in vitro producing liver stem cells from a sample of liver tissue, cultivating the liver stem cells in vitro for an increase in cell number. It has been found that the liver stem cells that are produced by the process of the invention can be cultivated and increased in number while maintaining their capability to differentiate into liver cells, especially into hepatocytes, cholangiocytes, and preferably also into LSEC. Accordingly, the process of the invention is suitable for producing liver stem cells that are autologous for the originator of the sample of liver tissue.